No conviction changes recorded
Upgrade to premium to see the full reasoning behind each conviction change.
Sign in to unlockFair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
24.8%/yr
±6.1% · revenue growth to justify current price
FCF-Based Reverse DCF
21.4%/yr
±3.5% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.
Sign in to unlock$823M backlog provides 6+ quarters of revenue visibility — the orders are there, it's execution that's lagging. Losses improved 21% YoY, and the trusted/classified computing moat remains intact. If management delivers even modest revenue acceleration with the existing backlog, re-rating from $28 to $35-40 is straightforward.
Turnaround is all talk, no proof. Gross margins compressed to 26% despite restructuring and a 28% R&D cut — that's cutting the seed corn. $938M in goodwill (64% of equity) is an impairment bomb if execution doesn't accelerate. No forward guidance suggests management has low confidence in near-term momentum.
Goodwill impairment, revenue growth below 5% for two consecutive quarters, debt covenant breach
Updated Mar 11
Operationally stabilizing (losses down 21% YoY) but turnaround unproven. $823.5M RPO strong, but 4.4% Q2 revenue growth minimal and margin compression continues. Deeply unprofitable with 2-3 year runw...